Format

Send to

Choose Destination
See comment in PubMed Commons below
Contemp Clin Trials. 2016 Mar;47:185-95. doi: 10.1016/j.cct.2016.01.003. Epub 2016 Jan 16.

Lung VITAL: Rationale, design, and baseline characteristics of an ancillary study evaluating the effects of vitamin D and/or marine omega-3 fatty acid supplements on acute exacerbations of chronic respiratory disease, asthma control, pneumonia and lung function in adults.

Author information

  • 1Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States; Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, United States; Harvard Medical School, Boston, MA, United States. Electronic address: diane.gold@channing.harvard.edu.
  • 2Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States; Harvard Medical School, Boston, MA, United States. Electronic address: reaal@channing.harvard.edu.
  • 3Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States; Harvard Medical School, Boston, MA, United States. Electronic address: vincent.carey@channing.harvard.edu.
  • 4Harvard Medical School, Boston, MA, United States; Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States; Department of Epidemiology, Harvard T.H.Chan School of Public Health, Boston, MA, United States. Electronic address: jmanson@rics.bwh.harvard.edu.
  • 5Harvard Medical School, Boston, MA, United States; Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States; Department of Epidemiology, Harvard T.H.Chan School of Public Health, Boston, MA, United States. Electronic address: jburing@rics.bwh.harvard.edu.
  • 6Harvard Medical School, Boston, MA, United States; Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States; Department of Epidemiology, Harvard T.H.Chan School of Public Health, Boston, MA, United States. Electronic address: ilee@rics.bwh.harvard.edu.
  • 7Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States. Electronic address: dgordon@rics.bwh.harvard.edu.
  • 8Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States. Electronic address: JWALTER@research.bwh.harvard.edu.
  • 9Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States. Electronic address: gfriedenberg@rics.bwh.harvard.edu.
  • 10Hankinson Consulting, Inc., Athens, GA, United States. Electronic address: john@occspiro.com.
  • 11Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States. Electronic address: PCOPELAND2@partners.org.
  • 12Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, United States. Electronic address: hgibson@hsph.harvard.edu.

Abstract

Laboratory and observational research studies suggest that vitamin D and marine omega-3 fatty acids may reduce risk for pneumonia, acute exacerbations of respiratory diseases including chronic obstructive lung disease (COPD) or asthma, and decline of lung function, but prevention trials with adequate dosing, adequate power, and adequate time to follow-up are lacking. The ongoing Lung VITAL study is taking advantage of a large clinical trial-the VITamin D and OmegA-3 TriaL (VITAL)--to conduct the first major evaluation of the influences of vitamin D and marine omega-3 fatty acid supplementation on pneumonia risk, respiratory exacerbation episodes, asthma control and lung function in adults. VITAL is a 5-year U.S.-wide randomized, double-blind, placebo-controlled, 2 × 2 factorial trial of supplementation with vitamin D3 ([cholecalciferol], 2000 IU/day) and marine omega-3 FA (Omacor® fish oil, eicosapentaenoic acid [EPA]+docosahexaenoic acid [DHA], 1g/day) for primary prevention of CVD and cancer among men and women, at baseline aged ≥50 and ≥55, respectively, with 5107 African Americans. In a subset of 1973 participants from 11 urban U.S. centers, lung function is measured before and two years after randomization. Yearly follow-up questionnaires assess incident pneumonia in the entire randomized population, and exacerbations of respiratory disease, asthma control and dyspnea in a subpopulation of 4314 randomized participants enriched, as shown in presentation of baseline characteristics, for respiratory disease, respiratory symptoms, and history of cigarette smoking. Self-reported pneumonia hospitalization will be confirmed by medical record review, and exacerbations will be confirmed by Center for Medicare and Medicaid Services data review.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT01728571.

KEYWORDS:

COPD; Lung function; Omega-3 fatty acids; Randomized clinical trial; Respiratory symptoms; Vitamin D

PMID:
26784651
PMCID:
PMC4818187
[Available on 2017-03-01]
DOI:
10.1016/j.cct.2016.01.003
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center